Heart Disease and Relaxin: New Actions for an Old Hormone
Trends in Endocrinology & Metabolism, ISSN: 1043-2760, Vol: 29, Issue: 5, Page: 338-348
2018
- 25Citations
- 38Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations25
- Citation Indexes25
- 25
- CrossRef20
- Captures38
- Readers38
- 38
Review Description
The hormone relaxin has long been recognized for its involvement in maternal adaptation during pregnancy. However, discoveries during the past two decades on the mechanism of action of relaxin, its family of receptors, and newly described roles in attenuating ischemia/reperfusion (I/R) injury, inflammation, and arrhythmias have prompted vast interest in exploring its therapeutic potential in cardiovascular disease. These observations inspired recently concluded clinical trials in patients with acute heart failure. This review discusses our current understanding of the protective signaling pathways elicited by relaxin in the heart, and highlights important new breakthroughs about relaxin signaling that may pave the way to more carefully designed future trials.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1043276018300304; http://dx.doi.org/10.1016/j.tem.2018.02.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85042903539&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29526354; https://linkinghub.elsevier.com/retrieve/pii/S1043276018300304; https://dx.doi.org/10.1016/j.tem.2018.02.008
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know